InsiderTrades

Form 4 for JANX Janux Therapeutics, Inc.

Accepted 2024-09-27 00:00:00 ET · period of report 2024-09-27 · accession 0001415889-24-024078 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-09-27 2024-09-27 JANX Meyer Andrew Hollman Chief Business Off S - Sale+OE $45.96 -50.0K 67.6K -43% -$2.30M
D 2024-09-27 2024-09-27 JANX Meyer Andrew Hollman Chief Business Off M - OptEx $4.21 +50.0K 117.6K +74% +$210.5K
D 2024-09-27 2024-09-27 JANX Meyer Andrew Hollman Chief Business Off M - OptEx $0.00 -50.0K 100.7K -33% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-09-27 S D 50,000 $45.96 67,592 D — — (F2) The weighted average sale price for the transaction reported was $45.9551 and the range of prices were between $45.55 and $46.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
2 Common Common Stock 2024-09-27 M A 50,000 $4.21 117,592 D — — (F1) Includes 1,189 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2021, 1,752 shares acquired under the Plan on May 13, 2022, 2,401 shares acquired under the Plan on May 15, 2023 and 2,834 shares acquired under the Plan on May 15, 2024.
3 Derivative Stock Option (right to buy) 2024-09-27 M D 50,000 $0.00 100,667 D $4.21 · — to 2031-03-09 50,000 Common Stock (F3) Immediately exercisable.